BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36627343)

  • 1. Pharmacological characterization of the small molecule 03A10 as an inhibitor of α-synuclein aggregation for Parkinson's disease treatment.
    Wang Q; Yao S; Yang ZX; Zhou C; Zhang Y; Zhang Y; Zhang L; Li JT; Xu ZJ; Zhu WL; Zhang NX; Ye Y; Feng LY
    Acta Pharmacol Sin; 2023 Jun; 44(6):1122-1134. PubMed ID: 36627343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
    Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
    Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
    Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
    Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity.
    Stoll AC; Sortwell CE
    Neurobiol Dis; 2022 Sep; 171():105804. PubMed ID: 35764290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease.
    Geng L; Gao W; Saiyin H; Li Y; Zeng Y; Zhang Z; Li X; Liu Z; Gao Q; An P; Jiang N; Yu X; Chen X; Li S; Chen L; Lu B; Li A; Chen G; Shen Y; Zhang H; Tian M; Zhang Z; Li J
    Mol Neurodegener; 2023 Dec; 18(1):94. PubMed ID: 38041169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
    Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
    Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein Propagation Mouse Models of Parkinson's Disease.
    Uemura N; Ueda J; Okuda S; Sawamura M; Takahashi R
    Methods Mol Biol; 2021; 2322():119-130. PubMed ID: 34043198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papaverine inhibits α-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinson's disease.
    Leem YH; Park JS; Park JE; Kim DY; Kang JL; Kim HS
    Biomed Pharmacother; 2020 Oct; 130():110576. PubMed ID: 32768884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits.
    Gezer AO; Kochmanski J; VanOeveren SE; Cole-Strauss A; Kemp CJ; Patterson JR; Miller KM; Kuhn NC; Herman DE; McIntire A; Lipton JW; Luk KC; Fleming SM; Sortwell CE; Bernstein AI
    Neurobiol Dis; 2020 Jul; 141():104947. PubMed ID: 32422283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the potential effects of α-synuclein aggregation on susceptibility to chronic stress in a mouse Parkinson's disease model.
    Alwani A; Maziarz K; Burda G; Jankowska-Kiełtyka M; Roman A; Łyszczarz G; Er S; Barut J; Barczyk-Woźnicka O; Pyza E; Kreiner G; Nalepa I; Chmielarz P
    Pharmacol Rep; 2023 Dec; 75(6):1474-1487. PubMed ID: 37725330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve.
    Uemura N; Yagi H; Uemura MT; Hatanaka Y; Yamakado H; Takahashi R
    Mol Neurodegener; 2018 May; 13(1):21. PubMed ID: 29751824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
    Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased AQP4 Expression Aggravates ɑ-Synuclein Pathology in Parkinson's Disease Mice, Possibly via Impaired Glymphatic Clearance.
    Cui H; Wang W; Zheng X; Xia D; Liu H; Qin C; Tian H; Teng J
    J Mol Neurosci; 2021 Dec; 71(12):2500-2513. PubMed ID: 33772424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
    Gu PS; Moon M; Choi JG; Oh MS
    J Nutr Biochem; 2017 Jan; 39():15-21. PubMed ID: 27741433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
    Ishola IO; Oloyo AK; Olubodun-Obadun TG; Godswill OD; Omilabu SA; Adeyemi OO
    Metab Brain Dis; 2023 Feb; 38(2):557-571. PubMed ID: 36401682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.